Stablemates Trial for NSCLC

[LaurenH]

For the first time, cancer researchers are offering patients with early stage lung cancer either surgery or stereotactic ablative radiotherapy (SABR) and comparing the results in a phase III clinical study called the Stablemates Trial.

 

SABR is a specialized form of radiation that has evolved in recent years to treat patients with just a few sessions – in this case just three treatments spread over eight days or less – using advanced imaging to deliver a higher dose. An early study has shown that SABR could be as effective as surgery among patients who did not qualify for surgery.

 

The primary objective of this study is to test the hypothesis that the 3-year overall survival in high risk operable patients with Stage I NSCLC is greater in patient who undergo SAbR as compared to standard sublobar resection (SR).

 

The new study now offers the same treatment to patients who are eligible for surgery but are at high risk for complications. To learn more and see a list of participating institutions, visit the trial web site.